patients

Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year

ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization,…

3 months ago

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

3 months ago

PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…

3 months ago

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…

3 months ago

Industry Leaders Join Ingenio Cares Mission to Redefine Access, Coordination, and Value in U.S. Healthcare

OAK BROOK, Ill., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Ingenio Care, Inc., an AI-driven digital health company, today announced the…

3 months ago

SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology

BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced…

3 months ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

October 17, 2025 16:05 ET  | Source: Jade Biosciences Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding…

3 months ago

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…

3 months ago

Not Just Pharmacy: How Medkart is Building India's Smartest Generic Medicine App

India’s pharmaceutical landscape is undergoing a vital transformation. Despite being home to one of the world’s largest medicine markets, millions…

3 months ago

Medkart Champions Generic Drug Quality Amid Rising Consumer Concerns

With growing scrutiny around the quality and reliability of generic medicines in India, Medkart, Gujarat’s largest generic-first pharmacy chain, is…

3 months ago